FDA Approves Trastuzumab and Hyaluronidase-oysk for Breast Cancer
On February 28, the Food and Drug Administration approved trastuzumab and hyaluronidase-oysk injection for subcutaneous use (Herceptin Hylecta, Genentech Inc.) for the treatment of HER2-overexpressing breast cancer.
In Person Conference & ConventionAugust 12, 2026 at 5:30 PM HST6600 Kalanianaʻole Highway suite 110, Honolulu, HI 96825, USARoy's Restaurants – Hawaii Kai, Honolulu
LOS 2026 Cancer Congress - National Oncology Updates
In Person Conference & ConventionAugust 14, 2026 at 11:00 AM CDT859 Convention Center Blvd, New Orleans, LA, USANew Orleans Marriott Warehouse Art District, New Orleans
In Person Conference & ConventionAugust 22, 2026 at 6:30 AM CDT300 East 9th Street, Coralville, IA, USAHyatt Regency Coralville Hotel & Conference Center, Coralville
